data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Keros Therapeutics
(NASDAQ:KROS)
$28.09
0.46[1.66%]
At close: Jul 1
$28.09
00
After Hours: 4:02PM EDT
Day High/Low27.15 - 28.36
52 Week High/Low24.38 - 68.29
Open / Close27.51 / 28.09
Float / Outstanding13.2M / 24M
Vol / Avg.303.4K / 217.2K
Mkt Cap675.1M
P/E-
50d Avg. Price37.99
Div / Yield-
Payout Ratio-
EPS-1.01
Total Float13.2M

Keros Therapeutics (NASDAQ:KROS), Quotes and News Summary

Keros Therapeutics (NASDAQ: KROS)

Day High/Low27.15 - 28.36
52 Week High/Low24.38 - 68.29
Open / Close27.51 / 28.09
Float / Outstanding13.2M / 24M
Vol / Avg.303.4K / 217.2K
Mkt Cap675.1M
P/E-
50d Avg. Price37.99
Div / Yield-
Payout Ratio-
EPS-1.01
Total Float13.2M
Benzinga - Jun 13, 2022, 8:07AM
Benzinga - Jun 10, 2022, 6:05AM
Benzinga - Jun 10, 2022, 6:04AM
Benzinga - May 18, 2022, 12:38PM
Benzinga - May 18, 2022, 12:25PM
Benzinga - May 18, 2022, 6:08AM
Benzinga - May 17, 2022, 4:01PM
Benzinga - May 5, 2022, 8:08AM
Benzinga - Mar 9, 2022, 4:04PM
Benzinga - Jan 31, 2022, 8:07AM
Benzinga - Dec 13, 2021, 4:12PM
Benzinga - Dec 13, 2021, 9:27AM
Benzinga - Dec 13, 2021, 8:12AM
Benzinga - Dec 13, 2021, 8:11AM
Benzinga - Nov 15, 2021, 8:16AM
Benzinga - Nov 8, 2021, 8:22AM
Benzinga - Nov 4, 2021, 9:22AM
Benzinga - Oct 4, 2021, 8:31AM
Benzinga - Sep 27, 2021, 2:31PM
load more
Sector: Health Care.Industry: Biotechnology
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Read More

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-04
REV
Q1 2022Est.ActualSurprise
EPS-0.860-1.010 -0.1500
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Keros Therapeutics Questions & Answers

Q
How do I buy Keros Therapeutics (KROS) stock?
A

You can purchase shares of Keros Therapeutics (NASDAQ: KROS) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are Keros Therapeutics's (KROS) competitors?
Q
What is the target price for Keros Therapeutics (KROS) stock?
A

The latest price target for Keros Therapeutics (NASDAQ: KROS) was reported by SVB Leerink on Tuesday, December 8, 2020. The analyst firm set a price target for 80.00 expecting KROS to rise to within 12 months (a possible 184.80% upside). 0 analyst firms have reported ratings in the last year.

Q
Current Stock Price for Keros Therapeutics (KROS)?
A

The stock price for Keros Therapeutics (NASDAQ: KROS) is $28.09 last updated July 1, 2022, 8:00 PM UTC.

Q
Does Keros Therapeutics (KROS) pay a dividend?
A

There are no upcoming dividends for Keros Therapeutics.

Q
When is Keros Therapeutics (NASDAQ:KROS) reporting earnings?
A

Keros Therapeutics’s Q2 earnings are confirmed for Thursday, August 4, 2022.

Q
Is Keros Therapeutics (KROS) going to split?
A

There is no upcoming split for Keros Therapeutics.

Q
What sector and industry does Keros Therapeutics (KROS) operate in?
A

Keros Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.